Company
Neotract
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
11
510(k), De Novo and PMA
Device trials
9
As lead sponsor, any status
Adverse event reports
92
Received Nov 1, 2025 to Nov 20, 2026
Recall records
2
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$117M
4 Form D offerings, 2009 to 2016
Equity
$117M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $12.8M raised of $15.0M sought, first sale Dec 29, 2016, 12 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Dec 29, 2016 | Equity | $12.8M | $15.0M | 12 | Rule 506(b) | Form D ↗Jan 6, 2017 |
3 more funding rounds with a free account
Company details
From the company's latest Form D.
- Legal name
- NEOTRACT INC
- Headquarters
- Pleasanton, California
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1356876 ↗
Executives, directors and promoters
As listed on the latest Form D.
9 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Neotract.
Latest FDA decisions
The 8 newest of 11 since 2015.
K232558 · Decided Sep 22, 2023 · 30 days after receipt
Device type: Implantable Transprostatic Tissue Retractor System (PEW) · GI, Urology & Nephrology
10 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-upWithdrawn
NCT05784558 · 0 participants · Start Jan 26, 2025 · Primary completion Jan 26, 2026
Device: UroLift System; Other Surgical Intervention · For: Benign Prostatic Hyperplasia
Sites: Pleasanton, California
8 more trials with a free account
Reports received
92
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
76
83% of reports
Injury reports
16
17% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 1 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 2 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 1 | 0 | 0 |
| Sep 24 | 0 | 0 | 1 | 0 |
| Oct 24 | 0 | 3 | 0 | 0 |
| Nov 24 | 0 | 1 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 1 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 2 | 3 | 0 | 0 |
| May 25 | 2 | 1 | 0 | 0 |
| Jun 25 | 4 | 1 | 0 | 0 |
| Jul 25 | 5 | 1 | 0 | 0 |
| Aug 25 | 3 | 1 | 0 | 0 |
| Sep 25 | 11 | 1 | 0 | 0 |
| Oct 25 | 0 | 1 | 0 | 0 |
| Nov 25 | 4 | 2 | 0 | 0 |
| Dec 25 | 3 | 2 | 0 | 0 |
| Jan 26 | 11 | 1 | 0 | 0 |
| Feb 26 | 2 | 2 | 0 | 0 |
| Mar 26 | 7 | 1 | 0 | 0 |
| Apr 26 | 5 | 1 | 0 | 0 |
| May 26 | 6 | 0 | 0 | 0 |
| Jun 26 | 8 | 1 | 0 | 0 |
| Jul 26 | 7 | 1 | 0 | 0 |
| Aug 26 | 11 | 5 | 0 | 0 |
| Sep 26 | 7 | 0 | 0 | 0 |
| Oct 26 | 5 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
The full in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
3 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1502-2022 · Started Jun 24, 2022 · Posted by FDA Aug 5, 2022
Reason given: There is the potential that during implant deployment, the device may not properly deliver a implant.
Cause as FDA categorized it: Under Investigation by firm · Device type: Implantable Transprostatic Tissue Retractor System (PEW)
1 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.